Alnylam Pharmaceuticals

ALNY61

$253.74arrow_drop_up0.09%$0.25

ALNY61

$253.74

arrow_drop_up0.09%$0.25

Performance History

Key Stats
Open	$253.98
Prev. Close	$253.35
EPS	-2.61
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	250.26	256.92
52 Week Range	141.98	291.20

Ratios







EPS	-2.61

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc (ALNY) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. ALNY is listed on the Nasdaq stock exchange under the ticker symbol ALNY.

ALNY's stock price history shows a steady upward trend over the past few years. The company's stock has experienced several significant price increases, reflecting positive developments in its pipeline and the overall growth of the RNAi therapeutics market. However, there have also been periods of volatility, as is common in the biotech industry.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Headquarters: Cambridge
Employees: 2002
Exchange: NASDAQ

add Alnylam Pharmaceuticals to watchlist

Keep an eye on Alnylam Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Alnylam Pharmaceuticals (ALNY)?

Alnylam Pharmaceuticals (ALNY) has a market capitalization of $32.73B. The average daily trading volume is 252.7, indicating the stock's liquidity and investor engagement.

help

What is Alnylam Pharmaceuticals 's (ALNY) price per share?

The current price per share for Alnylam Pharmaceuticals (ALNY) is $253.74. The stock has seen a price change of $0.25 recently, indicating a 0.1% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Alnylam Pharmaceuticals (ALNY)?

For Alnylam Pharmaceuticals (ALNY), the 52-week high is $291.2, which is 14.76% from the current price. The 52-week low is $141.98, the current price is 78.72% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Alnylam Pharmaceuticals (ALNY) a growth stock?

Alnylam Pharmaceuticals (ALNY) has shown an average price growth of -3.72% over the past three years. It has received a score of 70 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Alnylam Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Alnylam Pharmaceuticals (ALNY) stock price performance year to date (YTD)?

As of the latest data, Alnylam Pharmaceuticals (ALNY) has a year-to-date price change of 30.17%. Over the past month, the stock has experienced a price change of -11.56%. Over the last three months, the change has been -9.46%. Over the past six months, the figure is 69.09%. Looking at a longer horizon, the five-year price change stands at 115.84%.

help

Is Alnylam Pharmaceuticals (ALNY) a profitable company?

Alnylam Pharmaceuticals (ALNY) has a net income of -$440.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.02% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -15.35% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.83B, with a revenue growth rate of 76.23%, providing insight into the company's sales performance and growth. The gross profit is $1.52B. Operating income is noted at -$282.18M. Furthermore, the EBITDA is -$132.15M.